Juan P Cata1, John Villarreal2, Dinesh Keerty3, Dilip R Thakar2, Diane D Liu4, Anil K Sood5, Vijaya Gottumukkala2. 1. Departments of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Outcomes Research Consortium. Electronic address: jcata@mdanderson.org. 2. Departments of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Outcomes Research Consortium. 3. Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA 18510, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5. Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
STUDY OBJECTIVE: To assess the effect of perioperative beta blockers on recurrence and overall survival after non-small cell lung cancer surgery. DESIGN: Retrospective study. SETTING: Academic medical center. MEASUREMENTS: The medical records of patients with stage 1, 2, and 3a non-small cell lung cancer were divided into three different groups: those patients who never received beta blockers perioperatively, those receiving nonselective beta blockers within 60 days of surgery, and those taking selective beta blockers within 60 days of surgery. Recurrence-free survival and overall survival were the main clinical endpoints. Univariate log-rank tests and multivariate Cox proportional hazards models were used to assess the effects of selective beta blockers, nonselective beta blockers, or no beta blockers on recurrence-free survival and overall survival. MAIN RESULTS: The analysis included records of 435 patients. Univariate analyses showed that the use of both selective and nonselective beta blockers was associated with decreased recurrence-free survival (P = 0.014) and overall survival (P = 0.009). However, these findings were not sustained after adjusting for possible confounding variables in the multivariate analysis. The hazard ratios for recurrence-free survival (selective beta blockers vs no beta blocker use were: 1.304; 95% confidence intervals [CI] 0.973 - 1.747; P = 0.075; for nonselective beta blockers vs no beta blockers: 0.989; 95% CI 0.639 - 1.532; P = 0.962. The hazard ratios for overall survival were: selective beta blocker use vs no beta blockers: 1.335; 95% CI 0.966 - 1.846; P = 0.080; nonselective beta blocker use vs no beta blocker use: 1.108; 95% CI 0.678 - 1.812; P = 0.682. CONCLUSION: Administration of beta blockers during the perioperative period did not improve recurrence-free or overall survival in patients undergoing resection of non-small cell lung cancer.
STUDY OBJECTIVE: To assess the effect of perioperative beta blockers on recurrence and overall survival after non-small cell lung cancer surgery. DESIGN: Retrospective study. SETTING: Academic medical center. MEASUREMENTS: The medical records of patients with stage 1, 2, and 3a non-small cell lung cancer were divided into three different groups: those patients who never received beta blockers perioperatively, those receiving nonselective beta blockers within 60 days of surgery, and those taking selective beta blockers within 60 days of surgery. Recurrence-free survival and overall survival were the main clinical endpoints. Univariate log-rank tests and multivariate Cox proportional hazards models were used to assess the effects of selective beta blockers, nonselective beta blockers, or no beta blockers on recurrence-free survival and overall survival. MAIN RESULTS: The analysis included records of 435 patients. Univariate analyses showed that the use of both selective and nonselective beta blockers was associated with decreased recurrence-free survival (P = 0.014) and overall survival (P = 0.009). However, these findings were not sustained after adjusting for possible confounding variables in the multivariate analysis. The hazard ratios for recurrence-free survival (selective beta blockers vs no beta blocker use were: 1.304; 95% confidence intervals [CI] 0.973 - 1.747; P = 0.075; for nonselective beta blockers vs no beta blockers: 0.989; 95% CI 0.639 - 1.532; P = 0.962. The hazard ratios for overall survival were: selective beta blocker use vs no beta blockers: 1.335; 95% CI 0.966 - 1.846; P = 0.080; nonselective beta blocker use vs no beta blocker use: 1.108; 95% CI 0.678 - 1.812; P = 0.682. CONCLUSION: Administration of beta blockers during the perioperative period did not improve recurrence-free or overall survival in patients undergoing resection of non-small cell lung cancer.
Authors: Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin Journal: Am J Cancer Res Date: 2017-04-01 Impact factor: 6.166
Authors: Yi L Hwa; Qian Shi; Shaji K Kumar; Martha Q Lacy; Morie A Gertz; Prashant Kapoor; Francis K Buadi; Nelson Leung; David Dingli; Ronald S Go; Suzanne R Hayman; Wilson I Gonsalves; Stephen Russell; John A Lust; Yi Lin; S Vincent Rajkumar; Angela Dispenzieri Journal: Am J Hematol Date: 2016-11-18 Impact factor: 10.047
Authors: Janick Weberpals; Lina Jansen; Walter E Haefeli; Michael Hoffmeister; Martin Wolkewitz; Myrthe P P van Herk-Sukel; Pauline A J Vissers; Hermann Brenner Journal: Sci Rep Date: 2017-06-06 Impact factor: 4.379